Murray, Utah 84107


Some patients who have blood clots come down with a life-threatening condition known as Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which is high blood pressure only in the arteries of the lungs. This study seeks to understand more about the genetics causes of CTEPH by obtaining blood samples and examining family histories.

Study summary:

This project proposes to identify a cohort of Utah patients with CTEPH, and to perform a comprehensive analysis of family history and CTEPH risk factors in these patients, and in controls with acute pulmonary embolism (PE) and pulmonary arterial hypertension (PAH). Detailed family history interviews will be performed with all patients, and all enrolled patients will provide a blood sample for thrombophilia testing and for gene sequencing with the goal of identifying novel genetic variants that contribute to CTEPH risk.


Inclusion Criteria: - CTEPH cohort: 1. Confirmed CTEPH based on having undergone PEA surgery. 2. Strongly suspected CTEPH based on right heart catheterization data showing mPAP>26 and PCWP<15, and imaging demonstrating chronic thromboembolic disease (either ventilation/perfusion scan, CT pulmonary angiography, or conventional pulmonary angiography). - PE cohort: 1. PE diagnosed by CT pulmonary angiography or ventilation/perfusion scan within the preceding 24 months. 2. No evidence of PH at the time of enrollment (based on absence of dyspnea, exertional chest pain, or exertional presyncope on history, lack of physical exam findings of PH or right heart failure, and lack of signs of PH on objective data including echocardiography and/or right heart catheterization). 3. No evidence of chronic thromboembolic disease at the time of enrollment (based on chronic appearing thrombus on CT pulmonary angiography or conventional pulmonary angiography, or based on prior high probability ventilation/perfusion scan showing a similar pattern of perfusion defects). - PAH cohort: 1. Diagnosis of group 1 PAH. 2. Prior normal or low probability ventilation/perfusion scan. 3. No reported history of prior VTE events. 4. If available, all prior evaluations for VTE (including CT pulmonary angiography and Doppler ultrasound exams) must also be negative. Exclusion Criteria: - Under the age of 18



Primary Contact:

Principal Investigator
Mark Dodson, MD
Intermountain Health Care, Inc.

Valerie T Aston, MBA
Phone: 801-507-4606

Backup Contact:

David P Tomer, MS
Phone: 801-507-4694

Location Contact:

Murray, Utah 84107
United States

Valerie T Aston, MBA
Phone: 801-507-4606

Site Status: Recruiting

Data Source:

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.